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RAS interruption in type 1 diabetes mellitus.
Background. The enormous contribution of renin-
angiotensin system (RAS) interruption with ACE (angiotensin-
converting enzyme) inhibitors and angiotensin II receptor
blockers (ARB) in the treatment of diabetic nephropathy
has led to interest in the factors involved in angiotensin II
(Ang II) generation. In normal subjects, RAS interruption
using an ARB produced a 50% greater renal plasma flow
(RPF) rise than with an ACE inhibitor, suggesting a substantial
contribution of non-ACE pathways. Moreover, immunohis-
tochemistry studies in kidneys of overtly proteinuric diabetic
subjects showed up-regulation of chymase, an alternative Ang
II-generating enzyme. Our aim was to determine the degree to
which the non-ACE pathways contribute to RAS activation in
type 1 diabetes mellitus (DM).
Methods. Type 1 DM patients (N = 37, 14 M/23 F; age 31 ±
2 years; DM duration 16 ± 1.7 years; HbA1c 7.7.0 ± 0.3%)
were studied on a high-salt diet. They received captopril 25 mg
po one day and candesartan 16 mg po the next day. RPF and
glomerular filtration rate (GFR) were measured before and up
to 4 hours after drug administration.
Results. Both captopril and candesartan induced a significant
rise in RPF (baseline vs. peak <0.0001 for both), and the rise
was concordant for the 2 drugs (r = 0.77, P < 0.001). However,
the RPF responses were not significantly different between the
2 drugs (captopril 72 ± 11 mL/min/1.73m2, candesartan 75 ±
12, P = 0.841).
Conclusion. In predominantly normoalbuminuric, nor-
motensive type 1 DM, activation of the intrarenal RAS reflects
a mechanism involving primarily the classic ACE pathway.
The enormous contribution of renin-angiotensin sys-
tem (RAS) interruption with angiotensin-converting en-
zyme (ACE) inhibitors and angiotensin II receptor block-
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ers (ARBs) in the treatment of diabetic nephropathy has
led to renewed interest in the factors involved in an-
giotensin II (Ang II) generation and in Ang II receptor
blockade.
In normal subjects, RAS interruption using an ARB
produced a greater increase in renal plasma flow (RPF)
than did ACE inhibition, suggesting a substantial contri-
bution of non-ACE pathways in Ang II generation [1].
Recent immunohistochemistry studies on kidneys that
showed unequivocal evidence of diabetic nephropathy,
including diffuse glomerulosclerosis, nodular glomeru-
losclerosis, moderate to severe tubulointerstitial fibro-
sis, and vascular sclerosis, revealed an up-regulation of
chymase—an alternative Ang II-producing enzyme—
compared to normal kidneys [2]. This led us to apply a
functional measure of the contribution of non-ACE path-
ways to RAS activation in type 1 diabetes mellitus (DM).
METHODS
We studied 37 subjects with type 1 DM, diagnosed ac-
cording to accepted guidelines [3]. There were 37 sub-
jects, all Caucasian, 14 male and 23 female. Mean age ±
SEM was 31 ± 2 years, and duration of DM was 16 ±
1.7 years. The mean HbA1c was 7.7 ± 0.3%. Five had
microalbuminuria and 1 had overt proteinuria. Five had
retinopathy and two were hypertensive. Three were on an
ACE inhibitor; none were on ARB. There was no other
antihypertensive medication being used. Five had body
mass indices equal to or greater than 30 kg/m2. Baseline
characteristics are seen in Table 1.
The subjects were studied during admission to a
metabolic ward at the General Clinical Research Center
at the Brigham and Women’s Hospital, where sodium bal-
ance was achieved on a controlled diet. The protocol was
approved by the Institutional Review Board, and written
informed consent was obtained from each participant.
Antihypertensive medications, including ACE in-
hibitors, were discontinued 10 days before admission.
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Table 1. Demographic data and baseline characteristics of the type 1
DM subjects (N = 37)
Parameter
Age year ± SEM 31 ± 2
Gender M/F 14/23
Duration of DM year ± SEM 16 ± 1.7
Hemoglobin A1c% ± SEM 7.7 ± 0.3
Serum creatinine mg/dL ± SEM 0.87 ± 0.04
Nephropathy status (normo/micro/macroalbuminuric) 31/5/1
Hypertension status (normo/hypertensive) 35/2
Because a common convention in withdrawing drug ther-
apy is to allow five half lives to go by before undertaking
any other maneuver, this duration ensured more than
30 half lives for captopril and 20 half lives for other drugs
influencing the renin system. All participants were placed
on a high-salt isocaloric diet starting two days prior to ad-
mission and continuing throughout the hospitalization,
with a daily sodium intake of 200 mmol. Daily dietary
potassium (100 mmol) and fluid intake (2500 mL) were
constant. Twenty-four–hour urine samples were collected
daily and analyzed for sodium, potassium, creatinine, and
protein.
Renal hemodynamic and hormonal responses
to captopril and candesartan
Each subject participated in two experimental days.
On the morning of each study day, an intravenous
catheter was placed in each arm, one for infusion of para-
aminohippurate (PAH), inulin, and dextrose 5% in wa-
ter, and the other for blood sampling. A third intravenous
line was placed for continuous infusion of insulin, which
was started at 0.015 U/kg/hr. Blood glucose was measured
every 30 minutes (Precision PCX; Abbott Laboratories,
Chicago, IL, USA). The insulin infusion was adjusted to
maintain blood glucose well below the renal threshold,
but without inducing hypoglycemia, at levels of 100 to
140 mg/dL. The subjects were supine and had been fast-
ing for at least eight hours. Each study day began with a
60-minute baseline infusion of PAH and inulin prior to
drug administration to determine baseline renal plasma
flow (RPF) and glomerular filtration rate (GFR), respec-
tively. Hormonal measurements were made on blood
samples obtained at baseline and at four hours, and also
at eight hours on the candesartan day, after drug admin-
istration, while the subjects remained supine.
The study was designed to compare the renal hemo-
dynamic response to captopril and to candesartan. On
the first morning, the patients received captopril 25 mg
orally. On the next morning, the patients received can-
desartan 16 mg orally. These doses were chosen because
both represent the top of the relationship between dose
and RPF response [4]. The order by which the drugs had
been given and the time course of the blood draws had
been discussed previously and reflect the shorter half-life
of captopril [5].
Blood pressure was recorded during each infusion
by an automatic recording device (Dinamap; Critikon,
Tampa, FL, USA) at 5-minute intervals. Antihyperten-
sive medications were resumed upon discharge.
Renal clearance studies
PAH (Merck, Sharp & Dohme, Rahway, NJ, USA) and
inulin (Inutest; Fresenius Pharma Austria GmbH, Linz,
Austria) clearances were assessed after metabolic bal-
ance was achieved. A control blood sample was drawn,
and then loading doses of PAH (8 mg/kg) and inulin
(50 mg/kg) were given intravenously. A constant infu-
sion of PAH and inulin was initiated immediately at a
rate of 12 and 30 mg/min, respectively, with a Deltec 3000
pump (St. Paul, MN, USA). This achieved a plasma PAH
concentration in the middle of the range in which tubu-
lar secretion dominates excretion. At this plasma level
of PAH, clearance is independent of plasma concentra-
tion and represents approximately 90% of RPF when cor-
rected for individual body surface area. Likewise, at the
level of plasma inulin achieved, inulin clearance reflects
GFR. RPF and GFR determinations were made at base-
line (3 values taken 5 minutes apart) and at 45-minute
intervals thereafter for 225 minutes (∼4 hrs) while the
subjects were supine.
Laboratory procedures
Blood samples were collected on ice, spun immedi-
ately, and the plasma was frozen and stored at −70◦C
until assay. Urinary sodium and serum potassium levels
were measured using the ion selective electrode. PAH and
inulin were measured using an autoanalyzer technique.
Plasma renin activity (PRA) was determined by radioim-
munoassay. Hemoglobin A1C (HbA1C) was measured
by high-performance liquid chromatography. The normal
range is 4.4% to −6.3%.
Statistical analyses
Standard error of the mean (SEM) was used as the
index of dispersion. For renal hemodynamic data, the
baseline value taken was the average of the three pre-
drug determinations, and the peak response was the av-
erage of the two highest consecutive values. T test was
used to compare the renal vasodilatory responses to cap-
topril and candesartan. Paired t test was used to compare
baseline and peak responses for each drug. Pearson’s cor-
relation was used to test the association of the renal re-
sponse to candesartan with the response to captopril, the
association between baseline RPF and RPF response to
the two drugs, and the association between RPF response
and GFR response. A subgroup analysis comparing the
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Table 2. Baseline renal hemodynamics and the responses to captopril
and candesartan (mean ± SEM)
P value
Captopril vs.
Captopril Candesartan candesartan
Renal plasma flow mL/min/1.73m2
Baseline 590 ± 18 612 ± 21 0.418
Peak 662 ± 25 686 ± 27 0.509
Delta 72 ± 11 75 ± 12 0.841
Glomerular filtration rate mL/min/1.73m2
Baseline 122 ± 3.2 119 ± 3.0 0.576
Peak 121 ± 3.2 123 ± 3.4 0.589
Delta −1.1 ± 2.0 3.8 ± 1.9 0.072
responders to captopril versus the responders to can-
desartan was carried out using t test and chi-square test.
RESULTS
Captopril and candesartan both induced a significant
increase in RPF of 72 ± 11 and 75 ± 12 mL/min/1.73m2,
respectively (baseline vs. peak <0.0001 for both). The
baseline and peak renal plasma flow values were similar
for the captopril and the candesartan day (Table 2). The
RPF response was highly concordant for the two drugs
(r = 0.77, P < 0.001) (see Fig. 1). Baseline and peak GFR
did not significantly differ between the captopril and can-
desartan days (Table 2). However, comparison of base-
line versus peak GFR response to candesartan showed a
trend toward significance (P = 0.051); the GFR response
to captopril was not significant (baseline vs. peak P =
0.567).
Baseline PRA was not significantly different on the two
days (captopril day 0.50 ± 0.08, candesartan day 0.71 ±
0.12 ng Ang I/mL/hr, P = 0.136). There was also no signifi-
cant difference in the average blood glucose levels during
the study for the captopril and candesartan days (133 ±
6 vs. 142 ± 5 mg/dL, P = 0.258).
We evaluated the subset of 6 subjects with micro- (N =
5) or macroalbuminuria (N = 1). Again, the RPF re-
sponse to captopril was not significantly different from
the RPF response to candesartan (32 ± 11.3 vs. 48 ±
18.7 mL/min/1.73m2, P = 0.436) in these six subjects.
We then compared subjects who had a greater RPF re-
sponse to candesartan with subjects who had a greater
RPF response to captopril to see if any variable distin-
guished them. Eleven subjects had a RPF response to
candesartan that was greater than their response to capto-
pril by 30 mL/min/1.73m2 or more, and eight subjects had
a RPF response to captopril that was greater than their
response to candesartan by 30 mL/min/1.73m2. The fol-
lowing variables were similar between these two groups:
age (24 vs. 31 years, P = 0.177), duration of DM (12 vs.
10 years, P = 0.351), HbA1c (7.8 vs. 7.6%, P = 0.801),
BMI (25.5 vs. 24.9 kg/m2, P = 0.598), average blood glu-
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Fig. 1. Correlation between renal plasma flow (RPF) response to cap-
topril and RPF response to candesartan.
coses during the captopril study (135 vs. 158 mg/dL, P =
0.340) and the candesartan study (165 vs.158 mg/dL, P =
0.372), and baseline PRA during the captopril day (0.51
vs. 0.76 ng Ang I/mL/hr, P = 0.336) and the candesartan
day (0.77 vs. 1.00, P = 0.539). Likewise, gender, hyperten-
sion status, and nephropathy status were not significantly
different between these two groups.
DISCUSSION
The benefits of ACE inhibition in the management of
nephropathy in type 1 DM are well known [6]. More re-
cently, landmark studies conducted with ARBs showed
a reduced incidence of doubling of serum creatinine and
end-stage renal disease, and decreased albuminuria lev-
els in type 2 DM [7–9]. Blockade of Ang II generation or
action is key in management of diabetic nephropathy.
In our study, captopril and candesartan induced a sim-
ilar rise in RPF to our surprise, suggesting that non-ACE
pathways do not seem to play a major role in type 1 DM.
In nondiabetic subjects, the non-ACE pathway seems to
play an important role as RAS interruption with the ARB
candesartan produced a significantly larger RPF response
than the ACE inhibitor captopril [1]. Thus, an alternate,
non-ACE pathway for Ang II generation is operative in
nondiabetic subjects, accounting for 40% of the conver-
sion of Ang I to Ang II, and is not fully blocked by an
ACE inhibitor. Multiple observations underscore the im-
portance of this pathway [10, 11].
In the study by Hollenberg et al on normal subjects,
an ARB produced a greater increase in RPF than did an
ACE inhibitor, suggesting a substantial contribution of
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non-ACE pathways in Ang II generation [1]. Why would
the physiology in normal subjects, as reported by Hollen-
berg et al, be different from our type 1 DM subjects? Our
patients with type 1 DM had a similar age compared to the
normal subjects in Hollenberg et al’s study. The HbA1c in
our study on type 1 DM averaged 7.7%, and the average
blood glucose level during the studies was in the 130 to
145 mg/dL range, showing some degree of glucose dysreg-
ulation. In Hollenberg et al’s study on healthy subjects,
blood glucose was not measured during the study but the
fasting blood glucoses were normal. It has been shown
in multiple studies that hyperglycemia activates the RAS
[12–14]. The mechanism involves intracellular effects of
glucose rather than the physical osmolar effect of hyper-
glycemia, per se [15]. Why hyperglycemia tips the balance
in favor of the ACE pathway remains unclear. It is also
possible that enzymes other than chymases are respon-
sible for the greater RPF response to ARBs in healthy
subjects.
Is our finding that the non-ACE pathway does not play
a prominent role compatible with the immunohistochem-
istry study of Huang et al in diabetes [2]? Their study
showed up-regulation of both ACE and chymase expres-
sion. Chymase up-regulation correlated with blood pres-
sure increase, severity of proteinuria, and development
of diabetic glomerulosclerosis, tubulointerstitial fibrosis,
and arterial sclerosis, while ACE up-regulation corre-
lated with serum creatinine increase. There was greater
chymase up-regulation in their hypertensive DM versus
normotensive DM group; ACE expression did not show
the same correlation. What might be the crucial differ-
ence is that their study involved kidneys from type 2 DM
subjects with more advanced nephropathy, with a mean
proteinuria of 2.8 g/24 hours in the normotensive DM
group and 5.1 g/24 hours in the hypertensive DM group.
Racial breakdown was not reported and was unavailable
(personal communication with Dr. Hui Y. Lan). Our sub-
jects were mostly normotensive, normoalbuminuric, Cau-
casian type 1 DM, with normal creatinine levels.
Is there a subset of type 1 DM where the non-ACE
pathway contributes? We evaluated a small number of
subjects with microalbuminuria or overt proteinuria (N =
6). There was no difference between the renal hemo-
dynamic response to captopril and the response to can-
desartan in this subgroup, suggesting that the non-ACE
pathway also is not favored in this group, but this group
was small, enhancing the possibility of a type II error.
Comparison between subjects with a greater RPF re-
sponse to candesartan with the subjects that responded
better to captopril, likewise, did not uncover a feature
that predisposed to either direction.
Why would the classic (ACE) pathway be preferen-
tially active in type 1 DM? Part of the predilection for the
classic pathway may lie in the ACE gene polymorphisms
in diabetes. The insertion/deletion (I/D) polymorphism
of the ACE gene has been linked with the development
of diabetic nephropathy in Caucasian type 1 DM [16–19]
and Asian type 2 DM [20, 21], but association studies in
type 2 Caucasian DM were largely negative [20, 22, 23].
A possible limitation of this study involves the fact that
the sequence of drug administration was not random-
ized. We had addressed this in greater detail in a previ-
ous study [5]. In brief, captopril administration results in
a renal hemodynamic response that fades rapidly after
two to three hours [24], and PRA and RPF levels have
returned to baseline by 24 hours, prior to candesartan
administration.
Because the RPF responses to the two drugs were
highly correlated, the action of ACE inhibition reflected
primarily blockade of Ang II generation rather than the
generation of bradykinin and prostaglandins [25, 26].
Thus, not only does the ACE pathway dominate in the
conversion of angiotensin I to Ang II, but the action of
ACE inhibitors is mainly through blockade of this path-
way in type 1 DM.
CONCLUSION
In this group of type 1 DM subjects who are predom-
inantly normotensive, normoalbuminuric, and with nor-
mal creatinine levels, activation of the intrarenal RAS
reflects a mechanism primarily involving the classic ACE
pathway.
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